Vowst is the first and only FDA-approved orally administered microbiota-based therapeutic for the prevention of recurrent C. diff infection in adults.

"Disconnect" on anticoagulation between MDs and patients; NASH resolves after bariatric surgery; antiobesity medications are not weight-loss drugs; plus 2 more updates of note.

Dubbed the "twincretin," the GLP-1/GIP RA met weight and HgbA1c reduction endpoints, with nearly half of tirzepatide-treated patients achieving weight loss of at least 15%.

The AHRQ, Mayo Clinic, AMA, and National Academy of Medicine each recommend actions steps for all organizational levels to help build more supportive environments.

For persons diagnosed with obesity, a prescription antiobesity medication is just one part of optimal care that includes significant lifestyle change as well, says Caroline Apovian, MD.

In gummy products with melatonin, the actual amount ranged from 74% to 347% of the labeled quantity, according to a new analysis.

Your daily dose of clinical news you may have missed.

Apovian: GLP-1 receptor agonists are the first antiobesity medications to simulate human physiology, which is why they sustain weight loss and are meant for long-term use.

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

More than two-thirds of patients not receiving OAC were open to beginning treatment but many of their physicians were not, according to a study of PINNACLE Registry participants.

Your daily dose of clinical news you may have missed.

Women with prior HC-associated depression had a higher risk of developing a depressive episode during pregnancy and postpartum than women with non-HC-associated depression.

Women with ischemic heart disease who were metabolically unhealthy but fit were more than 50% more likely to experience a major adverse cardiovascular event.

Results from a prospective birth cohort study show an age-dependent association between RSV infection during infancy and childhood asthma.

Your daily dose of clinical news you may have missed.

The wearable tubeless insulin delivery device provides a fixed rate of continuous long-acting insulin for 72 hours, requiring no needles or injections.

In persons with biopsy-confirmed NASH, the probability of disease resolution was more than 3X greater after RGB or SG vs lifestyle intervention at 52 weeks.

Caroline Apovian, MD, highlights how drugs like semaglutide 2.4 mg treat the chronic relapsing disease of obesity and why a distinction from "weight-loss drugs" is critical.

When combined, fluvoxamine and inhaled budesonide appear more likely than either agent alone to reduce risk of early COVID-19 becoming severe, say TOGETHER investigators.

Your daily dose of clinical news you may have missed.